The American Society of Hematology (ASH) Annual Meeting and Exposition is the last big clinical conference of the year. As we head into 2024, which areas are set to attract investment with their latest datasets, and which are in danger of falling flat?
ASH will see the latest data reveals on CAR-T products, multiple myeloma, leukaemia and more. In this eBook, we’ve pulled together several of the most interesting players in the space to provide a snapshot of their pipelines and commercial outlook as they present their latest datasets at the conference.
We highlight Arcellx, Gilead, Regeneron, Vertex and MorphoSys ahead of their data reveals at ASH 2023.
